Top Markets
#1 Nesa Nesa +719.77%
#2 EXOD EXOD +22.78%
#3 Pons Pons +11.59%
#4 MetaDAO MetaDAO +11.24%
#5 Venom Venom +10.94%
#6 Ontology Gas Ontology Gas +9.15%
#7 Status Status +9.08%
#8 PondCoin PondCoin +8.53%
#9 Prom Prom +8.47%
#10 Wrapped NXM Wrapped NXM +7.71%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Classement en actions #19667
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Prix de l'action
$3.49
Dernière synchronisation: 2022-08-12
Capitalisation boursière
$154.10M
Changement (1 jour)
12.28%
Changement (1 an)
0.00%
Pays
DE
Échange InflaRx N.V. (IF0)

Catégorie

Healthcare
Le prix IF0 avec la capitalisation boursière de B
InflaRx N.V. InflaRx N.V.
IF0
$3.49
Capitalisation boursière de InflaRx N.V.(IF0)
Capitalisation boursière: $154.10M
En August 2026, InflaRx N.V. a une capitalisation boursière de $154.10M. Cela fait de InflaRx N.V. la 19667th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de InflaRx N.V. du 2019 au 2026
IF0 par rapport au top 5 des plus populaires stocks
Prix pour IF0 L’actif B La capitalisation boursière de B Résultats
InflaRx N.V. InflaRx N.V.
$116,562 $154.10M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.152T +3,343,508.54%
InflaRx N.V. InflaRx N.V.
$102,639 $154.10M
Apple Inc. Apple Inc.
AAPL
$4.537T +2,944,113.34%
InflaRx N.V. InflaRx N.V.
$94,303.21 $154.10M
Alphabet Inc. Alphabet Inc.
GOOG
$4.169T +2,705,012.68%
InflaRx N.V. InflaRx N.V.
$82,398.88 $154.10M
Microsoft Corporation Microsoft Corporation
MSFT
$3.642T +2,363,534.01%
InflaRx N.V. InflaRx N.V.
$63,449.27 $154.10M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.805T +1,819,959.23%